β-catenin is required for the tumorigenic behavior of triple-negative breast cancer cells

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Xu, Jinhua ^a,b   Prosperi, Jenifer R ^a,c   Choudhury, Noura ^a   Olopade, Olufunmilayo I ^a   Goss, Kathleen H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b JIANGHAN UNIVERSITY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CISPLATIN; DOXORUBICIN; LENTIVIRUS VECTOR; PUROMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CATENIN GENE; BMI 1 GENE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE C MYC; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; ANIMAL; BREAST; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

MUS;

ANIMALS; BETA CATENIN; BREAST; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84922523490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117097     Document Type: Article

References (36)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948. PMID: 21067385
2. Elsawaf Z, Sinn HP (2011) Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care (Basel) 6: 273-278.
3. Liedtke C, Bernemann C, Kiesel L, Rody A (2013) Genomic Profiling in Triple-Negative Breast Cancer. Breast Care (Basel) 8: 408-413.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692. PMID: 20877296
5. Guarneri V, Dieci MV, Conte P (2013) Relapsed triple-negative breast cancer: Challenges and treatment strategies. Drugs 73: 1257-1265. PMID: 23842749
6. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149: 1192-1205. PMID: 22682243
7. Prosperi JR, Goss KH (2010) A Wnt-ow of opportunity: Targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets 11: 1074-1088. PMID: 20545611
8. Prosperi JR, Khramtsov AI, Khramtsova GF, Goss KH (2011) Apc mutation enhances PyMT-induced mammary tumorigenesis. PLoS One 6: E29339. doi: 10.1371/journal.pone.0029339 PMID: 22216254
9. King TD, Suto MJ, Li Y (2012) The Wnt/beta-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 113: 13-18. PMID: 21898546
10. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262-4266. doi: 10.1073/pnas.060025397 PMID: 10759547
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. PMID: 9727977
12. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C (2006) Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 7: 1048-1056. PMID: 16951689
13. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53-57. PMID: 11326276
14. Yook JI, Li XY, Ota I, Hu C, Kim HS, et al. (2006) A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 8: 1398-1406. PMID: 17072303
15. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, et al. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 19: 301-309. PMID: 20056651
16. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920. doi: 10.2353/ajpath.2010.091125 PMID: 20395444
17. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, et al. (2011) beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 24: 209-231. PMID: 21076461
18. Odenwald MA, Prosperi JR, Goss KH (2013) APC/beta-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphology. BMC Cancer 13: 12. doi: 10.1186/1471-2407-13-12 PMID: 23302090
19. Li B, Gordon GM, Du CH, Xu J, DuW(2010) Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell 17: 469-480. doi: 10.1016/j.ccr.2010.03.019 PMID: 20478529
20. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, et al. (2010) CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat 120: 593-601. PMID: 19466541
21. Bakker ER, Hoekstra E, Franken PF, Helvensteijn W, van Deurzen CH, et al. (2013) beta-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer. Oncogene 32: 4579-4585. PMID: 23045279
22. DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, et al. (2009) A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69: 5364-5373. doi: 10.1158/0008-5472.CAN-08-4135 PMID: 19549913
23. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE (2009) WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 11: R32. doi: 10.1186/bcr2317 PMID: 19473496
24. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850. PMID: 15829953
25. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653. PMID: 18385740
26. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, et al. (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468-476. PMID: 20418870
27. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. doi: 10.1073/pnas. 0530291100 PMID: 12629218
28. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567. doi: 10.1016/j.stem.2007.08.014 PMID: 18371393
29. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, et al. (2008) The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53. doi: 10.1186/bcr2108 PMID: 18559090
30. Wu ZQ, Brabletz T, Fearon E, Willis AL, Hu CY, et al. (2012) Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci U S A 109: 11312-11317. doi: 10.1073/pnas.1203015109 PMID: 22745173
31. Joensuu H, Gligorov J (2012) Adjuvant treatments for triple-negative breast cancers. Ann Oncol 23 Suppl 6: Vi40-45. PMID: 23012301
32. von Minckwitz G, Martin M (2012) Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 23 Suppl 6: Vi35-39. PMID: 23012300
33. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, et al. (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153. doi: 10.1200/JCO.2009.22.4725 PMID: 20100965
34. Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-3162. PMID: 20530697
35. Wend P, Runke S, Wend K, Anchondo B, Yesayan M, et al. (2013) WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 5: 264-279. doi: 10.1002/emmm.201201320 PMID: 23307470
36. Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910. PMID: 18004397